Business

Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques

BEDFORD, Mass.--(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with

articleAnika Therapeutics Inc.December 10, 20194/company/anika-therapeutics-inc/news/anika-commences-full-us-commercial-launch-of-tactoset-bone-repair-therapy-at-orthopaedic-summit-2019-evolving-techniques
Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques

About this update from Anika Therapeutics Inc.

[{"type":"text","content":" BEDFORD, Mass.--(BUSINESS WIRE)--\nAnika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced it will commence the full U.S. commercial launch of TACTOSET, its surgically delivered therapy for bone repair procedures, at the Orthopaedic Summit 2019: Evolving Techniques (OSET), which will take place December 11-14, 2019 at the Bellagio Hotel in Las Vegas, NV.\n\n\n“We are proud to commence the full-scale launch of TACTOSET, our first surgically delivered regenerative therapy in the U.S. sold through our hybrid commercial sales channel,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “TACTOSET has already surpassed our initial goals of onboarding five distributor agents and being present in ten surgical centers in 2019. OSET is the perfect venue to take the next step with the therapy and mark this important milestone in Anika’s transformation to a global commercial company as a premier gathering of Sports Medicine and Arthroscopic Surgery Orthopedists from across the globe.”\n\n\nTACTOSET has been developed for the treatment of bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. TACTOSET is Anika’s first product to launch under its U.S.-based hybrid commercial model. This therapy combines calcium phosphate, an established precursor to the mineral component of bone, with Anika’s proprietary hyaluronic acid, which enhances flow and tactile feel during administration to improve ease of use and procedural efficiency.\n\n\n“I continue to be pleased with TACTOSET’s unique ease-of-use in my surgical practice, which has led to a reduction in operating room time for the procedure,” said Dr. John Tierney, an Orthopaedic Surgeon at New England Baptist Hospital, President of the Greater Boston Orthopaedic Center. “I am already a repeat user, and I believe that many of the orthopaedic surgeons in attendance at OSET 2019 will recognize the differentiated benefits that this product can provide to their practices.”\n\n\nAnika will showcase its TACTOSET bone repair therapy at OSET booths 112 and 114. The Orthopaedic Summit, attended by over 900 of the world’s leading orthopaedic professionals, will feature cut...

More updates from Anika Therapeutics Inc.